Shikeda masks slow second quarter for buyouts
The money spent on biopharma acquisitions in the second quarter looks huge, but most of the total is down to one deal.
Back to the future for small caps, but not all benefit
Oncology-focused smaller biotechs reap rich rewards, but generics groups face hard times.
